Kenneth Bate sold $7.1M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 20,000 shares at an average of $356.44, traded Feb 27, 2025, filed Feb 28, 2025.
Score components
- +15RoleDirector
- +25Trade size$7.1M at market
- +20Share of holdings soldSold 91% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-009076, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 27, 2025 | MOption exercise Common Stock | +6,000 | $111.06 | $666k | 7,912 | Feb 28, 2025 |
| Feb 27, 2025 | MOption exercise Common Stock | +9,470 | $65.06 | $616k | 17,382 | Feb 28, 2025 |
| Feb 27, 2025 | MOption exercise Common Stock | +4,530 | $9.45 | $43k | 21,912 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -100 | $351.01 | $35k | 21,812 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -500 | $351.99 | $176k | 21,312 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -238 | $353.83 | $84k | 21,074 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -8,545 | $355.08 | $3.0M | 12,529 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -2,791 | $356.51 | $995k | 9,738 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -2,038 | $357.27 | $728k | 7,700 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -3,548 | $358.33 | $1.3M | 4,152 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -2,024 | $359.21 | $727k | 2,128 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock | -216 | $360.07 | $78k | 1,912 | Feb 28, 2025 |
| Feb 27, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -6,000 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Feb 27, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -9,470 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Feb 27, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -4,530 | $0.00 | $0 | 5,470 | Feb 28, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | Fred B Craves director | $5.1M 15,470 shares | -4% | |
| 26Weak | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier SVP and CFO | $83k 258 shares | -2% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier SVP and CFO | $637k 1,961 shares | -22% | |
| 34Weak | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $598k 1,834 shares | -18% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $139k 415 shares | -5% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | James M Daly director | $5.4M 15,470 shares | -89% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $116k 347 shares | -3% | |
| 31Weak | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $76k 277 shares | -3% | |
| 53Moderate | MADRIGAL PHARMACEUTICALS, INC. | Fred B Craves director | $1.1M 3,600 shares | -25% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.